Reveal Biosciences Secures Series A Funding Led by Intel Capital to Advance AI-Powered Digital Pathology Platform

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on April 2 (U.S. local time), Reveal Biosciences, headquartered in San Diego, California, announced the completion of its Series A financing round, with the amount undisclosed. The round was led by Intel Capital, with participation from GNI Group and PP Capital. Additionally, Ranjeet Alexis, Managing Director at Intel Capital, will join the Board of Directors of Reveal Biosciences.

Reveal Biosciences is set to leverage this funding round to expand its ImageDx online analytics platform and launch additional AI-powered clinical decision support tools. As a cutting-edge technology grounded in objective data, ImageDx empowers clinicians to deliver enhanced patient care and identify more effective therapeutic options.

Reveal Biosciences is a computational pathology company co-founded by Casey Laris and Claire Weston in August 2012. The company is dedicated to characterizing and detecting diseases through data-driven pathology, thereby improving the global healthcare industry. Leveraging a solid medical foundation and specialized computational expertise, Reveal Biosciences has remained at the forefront of digital pathology.

Reveal Biosciences’ proprietary ImageDx platform provides pathologists and researchers with a suite of valuable quantitative data, helping to enhance and advance patient care. To date, the comprehensive data laboratory developed by Reveal Biosciences using ImageDx technology has accelerated research for more than 300 leading biopharmaceutical companies and academic institutions. This advanced laboratory enables client companies to access high-performance pathology artificial intelligence algorithms at scale.

“ImageDx has been widely applied in clinical trials and medical pathology research,” said Dr. Claire Weston, Founder and CEO of Reveal Biosciences. “To date, ImageDx technology has provided information services to more than 300 healthcare institutions. Our specialized approach to data integration enables the rapid, large-scale generation of AI algorithms for pathology. With this financing, we are pleased to expand our ecosystem of researchers, pathologists, and technologists, working together to pioneer new paradigms in AI-driven healthcare.”

Naveen Rao, Vice President of Intel’s Artificial Intelligence Products Group, stated, “Artificial intelligence is a technology accelerating the development of the healthcare industry and has already demonstrated significant potential to impact medical research and benefit patients.”

Intel Capital is the investment arm of Intel Corporation and one of the world’s most powerful venture capital firms. Established in 1991 and headquartered in Santa Clara, California, the division primarily invests in innovative startups, focusing on disruptive technologies such as artificial intelligence, proprietary technologies, data centers, cloud computing, 5G, and next-generation computing. To date, Intel Capital has invested $12.4 billion in 1,554 companies worldwide and participated in the mergers or acquisitions of 670 portfolio companies.

(Compiled by: Wang Chan)